UNSPSC 51273932: Dibucaine/diperodon

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE700. This VA Drug Class (DE700) classifies this compound as belonging to the group LOCAL ANESTHETICS, TOPICAL.

UNSPSC 51273932 Dibucaine/diperodon is a Commodity code that nominally names a single local anesthetic product, but recent state and local solicitations do not reflect procurement of this specific agent. Instead, the opportunities tagged to this code involve broader pharmaceutical supply contracts — naloxone and drug deactivation systems for public health response, direct-to-manufacturer prescription fulfillment arrangements, and multi-source generic pharmaceuticals and OTC products through cooperative purchasing networks. The actual buying activity under this code designation spans county health departments, state health and human services agencies, and multistate cooperative purchasing alliances seeking to establish standing supply agreements for emergency medications, controlled-substance management systems, and generic pharmaceutical distribution to public facilities. Issuing bodies include Seminole County (Florida) Community Health, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), representing a mix of local health authorities, state agencies, and regional cooperative vehicles.

Recent opportunities show activity concentrated in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the County Community Health Building in Sanford, Florida, with an initial two-year term and one-year renewal option and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program serving self-insured state employee health plans. MMCAP, administered by Minnesota's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local government facilities across participating jurisdictions including Oregon, with proposals due March 26, 2026, evaluation weighted 75 percent on price competitiveness, and contract effectiveness July 1, 2026.